{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:14:07Z","timestamp":1783466047072,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chong Kun Dang Pharmaceutical Corporation"},{"name":"young researcher grant from the Korea Society for Transplantation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50453-x","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:23:55Z","timestamp":1777303435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel strategy to prolong heart allograft survival in a mouse model using soluble programmed death ligand-1 combined with tacrolimus"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1317-6502","authenticated-orcid":false,"given":"Sang Oh","family":"Yun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2722-7817","authenticated-orcid":false,"given":"Kyo Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-2278","authenticated-orcid":false,"given":"Jae Berm","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7221-2737","authenticated-orcid":false,"given":"Jung-Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung Hee","family":"Sonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. Kyung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"50453_CR1","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","volume":"191","author":"JR Azzi","year":"2013","unstructured":"Azzi, J. R., Sayegh, M. H. & Mallat, S. G. Calcineurin inhibitors: 40 years later, can\u2019t live without. J. Immunol. 191, 5785\u20135791 (2013).","journal-title":"J. Immunol."},{"key":"50453_CR2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMra011295","volume":"346","author":"M Pascual","year":"2002","unstructured":"Pascual, M., Theruvath, T., Kawai, T., Tolkoff-Rubin, N. & Cosimi, A. B. Strategies to improve long-term outcomes after renal transplantation. N Engl. J. Med. 346, 580\u2013590. https:\/\/doi.org\/10.1056\/NEJMra011295 (2002).","journal-title":"N Engl. J. Med."},{"key":"50453_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ackd.2019.08.006","volume":"27","author":"SS Farouk","year":"2020","unstructured":"Farouk, S. S. & Rein, J. L. The Many Faces of Calcineurin Inhibitor Toxicity-What the FK? Adv. Chronic Kidney Dis. 27, 56\u201366. https:\/\/doi.org\/10.1053\/j.ackd.2019.08.006 (2020).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"50453_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/jlts.2000.9737","volume":"6","author":"SC Textor","year":"2000","unstructured":"Textor, S. C., Taler, S. J., Canzanello, V. J., Schwartz, L. & Augustine, J. E. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl. 6, 521\u2013530. https:\/\/doi.org\/10.1053\/jlts.2000.9737 (2000).","journal-title":"Liver Transpl."},{"key":"50453_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","volume":"48","author":"T Vanhove","year":"2016","unstructured":"Vanhove, T., Annaert, P. & Kuypers, D. R. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab. Rev. 48, 88\u2013112. https:\/\/doi.org\/10.3109\/03602532.2016.1151037 (2016).","journal-title":"Drug Metab. Rev."},{"key":"50453_CR6","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1161\/01.CIR.103.17.2144","volume":"103","author":"H Valantine","year":"2001","unstructured":"Valantine, H. et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation 103, 2144\u20132152 (2001).","journal-title":"Circulation"},{"key":"50453_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","volume":"4","author":"M Naesens","year":"2009","unstructured":"Naesens, M., Kuypers, D. R. & Sarwal, M. Calcineurin inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 4, 481\u2013508 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"50453_CR8","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1159\/000351648","volume":"37","author":"N Issa","year":"2013","unstructured":"Issa, N., Kukla, A. & Ibrahim, H. N. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am. J. Nephrol. 37, 602\u2013612. https:\/\/doi.org\/10.1159\/000351648 (2013).","journal-title":"Am. J. Nephrol."},{"key":"50453_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bcp.12289","volume":"78","author":"C Cornu","year":"2014","unstructured":"Cornu, C. et al. Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 78, 24\u201332. https:\/\/doi.org\/10.1111\/bcp.12289 (2014).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"50453_CR10","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(98)07493-5","volume":"353","author":"MD Denton","year":"1999","unstructured":"Denton, M. D., Magee, C. C. & Sayegh, M. H. Immunosuppressive strategies in transplantation. Lancet 353, 1083\u20131091. https:\/\/doi.org\/10.1016\/S0140-6736(98)07493-5 (1999).","journal-title":"Lancet"},{"key":"50453_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jclinpath-2017-204853","volume":"71","author":"A Kythreotou","year":"2018","unstructured":"Kythreotou, A., Siddique, A., Mauri, F. A., Bower, M. & Pinato, D. J. PD-L1. J. Clin. Pathol. 71, 189\u2013194 (2018).","journal-title":"J. Clin. Pathol."},{"key":"50453_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/0008-5472.CAN-14-1215","volume":"75","author":"J Li","year":"2015","unstructured":"Li, J. et al. PD-1\/SHP-2 inhibits Tc1\/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 75, 508\u2013518. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1215 (2015).","journal-title":"Cancer Res."},{"key":"50453_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.celrep.2018.03.026","volume":"23","author":"G Rota","year":"2018","unstructured":"Rota, G. et al. Shp-2 is dispensable for establishing T cell exhaustion and for PD-1 signaling in vivo. Cell. Rep. 23, 39\u201349 (2018).","journal-title":"Cell. Rep."},{"key":"50453_CR14","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.4049\/jimmunol.0900080","volume":"182","author":"S Chikuma","year":"2009","unstructured":"Chikuma, S. et al. PD-1-mediated suppression of IL-2 production induces CD8\u2009+\u2009T cell anergy in vivo. J. Immunol. 182, 6682\u20136689. https:\/\/doi.org\/10.4049\/jimmunol.0900080 (2009).","journal-title":"J. Immunol."},{"key":"50453_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi, M. et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol. Cancer. 21, 28. https:\/\/doi.org\/10.1186\/s12943-021-01489-2 (2022).","journal-title":"Mol. Cancer"},{"key":"50453_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.autrev.2013.05.003","volume":"12","author":"E Gianchecchi","year":"2013","unstructured":"Gianchecchi, E., Delfino, D. V. & Fierabracci, A. Recent insights into the role of the PD-1\/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun. rev. 12, 1091\u20131100 (2013).","journal-title":"Autoimmun. rev."},{"issue":"12","key":"50453_CR17","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.3390\/cancers13123034","volume":"13","author":"C Bailly","year":"2021","unstructured":"Bailly, C., Thuru, X. & Quesnel, B. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers 13 (12), 3034 (2021).","journal-title":"Cancers"},{"key":"50453_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","volume":"104","author":"M Tio","year":"2018","unstructured":"Tio, M. et al. Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection. Eur. J. Cancer. 104, 137\u2013144 (2018).","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"50453_CR19","doi-asserted-by":"publisher","first-page":"9354","DOI":"10.21037\/apm-21-999","volume":"10","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. Prognosis after liver transplantation in patients treated with anti-PD-1 immunotherapy for advanced hepatocellular carcinoma: Case series. Annals Palliat. Med. 10 (9), 9354\u20139361 (2021).","journal-title":"Annals Palliat. Med."},{"key":"50453_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CJI.0000000000000188","volume":"40","author":"JK Winkler","year":"2017","unstructured":"Winkler, J. K. et al. Safe administration of an anti-PD-1 antibody to kidney-transplant patients: 2 clinical cases and review of the literature. J. Immunother. 40, 341\u2013344 (2017).","journal-title":"J. Immunother."},{"key":"50453_CR21","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.4049\/jimmunol.174.11.6648","volume":"174","author":"T Ito","year":"2005","unstructured":"Ito, T. et al. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J. Immunol. 174, 6648\u20136656. https:\/\/doi.org\/10.4049\/jimmunol.174.11.6648 (2005).","journal-title":"J. Immunol."},{"key":"50453_CR22","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.4049\/jimmunol.179.8.5204","volume":"179","author":"K Tanaka","year":"2007","unstructured":"Tanaka, K. et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J. Immunol. 179, 5204\u20135210. https:\/\/doi.org\/10.4049\/jimmunol.179.8.5204 (2007).","journal-title":"J. Immunol."},{"key":"50453_CR23","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/CIRCULATIONAHA.107.741025","volume":"117","author":"J Yang","year":"2008","unstructured":"Yang, J. et al. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation 117, 660\u2013669 (2008).","journal-title":"Circulation"},{"key":"50453_CR24","doi-asserted-by":"crossref","unstructured":"Nakajima, Y., Chamoto, K., Oura, T. & Honjo, T. Critical role of the CD44lowCD62Llow CD8\u2009+\u2009T cell subset in restoring antitumor immunity in aged mice. Proceedings of the National Academy of Sciences 118, e2103730118 (2021).","DOI":"10.1073\/pnas.2103730118"},{"key":"50453_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00011-019-01237-9","volume":"68","author":"F Yang","year":"2019","unstructured":"Yang, F. et al. Adoptive transfer of IFN-\u03b3-induced M-MDSCs promotes immune tolerance to allografts through iNOS pathway. Inflamm. Res. 68, 545\u2013555. https:\/\/doi.org\/10.1007\/s00011-019-01237-9 (2019).","journal-title":"Inflamm. Res."},{"key":"50453_CR26","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.4049\/jimmunol.169.11.6546","volume":"169","author":"E Ozkaynak","year":"2002","unstructured":"Ozkaynak, E. et al. Programmed death-1 targeting can promote allograft survival. J. Immunol. 169, 6546\u20136553. https:\/\/doi.org\/10.4049\/jimmunol.169.11.6546 (2002).","journal-title":"J. Immunol."},{"key":"50453_CR27","doi-asserted-by":"publisher","first-page":"107331","DOI":"10.1016\/j.carpath.2021.107331","volume":"54","author":"M Bishawi","year":"2021","unstructured":"Bishawi, M. et al. PD-1 and PD-L1 expression in cardiac transplantation. Cardiovasc. Pathol. 54, 107331. https:\/\/doi.org\/10.1016\/j.carpath.2021.107331 (2021).","journal-title":"Cardiovasc. Pathol."},{"key":"50453_CR28","doi-asserted-by":"publisher","first-page":"e86551","DOI":"10.1371\/journal.pone.0086551","volume":"9","author":"EI Sega","year":"2014","unstructured":"Sega, E. I. et al. Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PloS one. 9, e86551 (2014).","journal-title":"PloS one"},{"key":"50453_CR29","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1097\/01.tp.0000282865.84743.9c","volume":"84","author":"T Haudebourg","year":"2007","unstructured":"Haudebourg, T. et al. Depletion of LAG-3 positive cells in cardiac allograft reveals their role in rejection and tolerance. Transplantation 84, 1500\u20131506 (2007).","journal-title":"Transplantation"},{"key":"50453_CR30","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/1535-7163.MCT-18-0836","volume":"18","author":"S Ghosh","year":"2019","unstructured":"Ghosh, S. et al. TSR-033, a novel therapeutic antibody targeting LAG-3, enhances T-cell function and the activity of PD-1 blockade in vitro and in vivo. Mol. Cancer Ther. 18, 632\u2013641 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"50453_CR31","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/eji.201646837","volume":"47","author":"D Cibri\u00e1n","year":"2017","unstructured":"Cibri\u00e1n, D. & S\u00e1nchez-Madrid, F. CD69: from activation marker to metabolic gatekeeper. Eur. J. Immunol. 47, 946\u2013953 (2017).","journal-title":"Eur. J. Immunol."},{"key":"50453_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.molmed.2013.07.006","volume":"19","author":"R Gonz\u00e1lez-Amaro","year":"2013","unstructured":"Gonz\u00e1lez-Amaro, R., Cort\u00e9s, J. R., S\u00e1nchez-Madrid, F. & Mart\u00edn, P. Is CD69 an effective brake to control inflammatory diseases? Trends Mol. Med. 19, 625\u2013632 (2013).","journal-title":"Trends Mol. Med."},{"key":"50453_CR33","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1128\/MCB.00456-10","volume":"30","author":"P Mart\u00edn","year":"2010","unstructured":"Mart\u00edn, P. et al. CD69 association with Jak3\/Stat5 proteins regulates Th17 cell differentiation. Mol. Cell. Biol. 30, 4877\u20134889 (2010).","journal-title":"Mol. Cell. Biol."},{"key":"50453_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nri3701","volume":"14","author":"KN Pollizzi","year":"2014","unstructured":"Pollizzi, K. N. & Powell, J. D. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat. Rev. Immunol. 14, 435\u2013446 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"50453_CR35","doi-asserted-by":"publisher","first-page":"667834","DOI":"10.3389\/fimmu.2021.667834","volume":"12","author":"MH Ravindranath","year":"2021","unstructured":"Ravindranath, M. H., Hilali, E., Filippone, E. J. & F. & The impact of inflammation on the immune responses to transplantation: tolerance or rejection? Front. Immunol. 12, 667834 (2021).","journal-title":"Front. Immunol."},{"key":"50453_CR36","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.3324\/haematol.2019.216101","volume":"104","author":"P Merli","year":"2019","unstructured":"Merli, P. et al. Role of interferon-\u03b3 in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation. Haematologica 104, 2314\u20132323. https:\/\/doi.org\/10.3324\/haematol.2019.216101 (2019).","journal-title":"Haematologica"},{"key":"50453_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cytogfr.2018.04.001","volume":"41","author":"P Ro\u017eman","year":"2018","unstructured":"Ro\u017eman, P. & \u0160vajger, U. The tolerogenic role of IFN-\u03b3. Cytokine Growth Factor Rev. 41, 40\u201353. https:\/\/doi.org\/10.1016\/j.cytogfr.2018.04.001 (2018).","journal-title":"Cytokine Growth Factor Rev."},{"key":"50453_CR38","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1016\/j.healun.2004.03.010","volume":"23","author":"H Eisen","year":"2004","unstructured":"Eisen, H. & Ross, H. Optimizing the immunosuppressive regimen in heart transplantation. J. heart lung transplantation. 23, S207\u2013S213 (2004).","journal-title":"J. heart lung transplantation"},{"key":"50453_CR39","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0041-1345(02)03101-9","volume":"34","author":"M Weis","year":"2002","unstructured":"Weis, M. Cardiac allograft vasculopathy: Prevention and treatment options. Transpl. Proc. 34, 1847\u20131849 (2002).","journal-title":"Transpl. Proc."},{"key":"50453_CR40","doi-asserted-by":"crossref","unstructured":"Young, J. B. Vol. 100 458\u2013460 (Am Heart Assoc, 1999).","DOI":"10.1161\/01.CIR.100.5.458"},{"key":"50453_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cvm-1-3-166","volume":"1","author":"J Kobashigawa","year":"2000","unstructured":"Kobashigawa, J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Trials 1, 1\u20136 (2000).","journal-title":"Trials"},{"key":"50453_CR42","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1080\/10428194.2019.1581934","volume":"60","author":"EV Batorov","year":"2019","unstructured":"Batorov, E. V. et al. Increased circulating CD3(+) T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma. Leuk. Lymphoma. 60, 2488\u20132497. https:\/\/doi.org\/10.1080\/10428194.2019.1581934 (2019).","journal-title":"Leuk. Lymphoma"},{"key":"50453_CR43","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3892\/mco.2020.2027","volume":"12","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. High proportions of CD3(+) T cells in grafts delayed lymphocyte recovery and reduced overall survival in haploidentical peripheral blood stem cell transplantation. Mol. Clin. Oncol. 12, 574\u2013580. https:\/\/doi.org\/10.3892\/mco.2020.2027 (2020).","journal-title":"Mol. Clin. Oncol."},{"key":"50453_CR44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00428-017-2260-6","volume":"472","author":"A Moon","year":"2018","unstructured":"Moon, A. et al. Development of CD3 cell quantitation algorithms for renal allograft biopsy rejection assessment utilizing open source image analysis software. Virchows Arch. 472, 259\u2013269. https:\/\/doi.org\/10.1007\/s00428-017-2260-6 (2018).","journal-title":"Virchows Arch."},{"key":"50453_CR45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ki.2010.95","volume":"78","author":"S Swaminathan","year":"2010","unstructured":"Swaminathan, S. Programmed to direct alloimmunity. Kidney Int. 78, 8\u20139 (2010).","journal-title":"Kidney Int."},{"key":"50453_CR46","doi-asserted-by":"publisher","first-page":"e01099","DOI":"10.1002\/cti2.1099","volume":"9","author":"M Atif","year":"2020","unstructured":"Atif, M., Conti, F., Gorochov, G., Oo, Y. H. & Miyara, M. Regulatory T cells in solid organ transplantation. Clin. translational Immunol. 9, e01099 (2020).","journal-title":"Clin. translational Immunol."},{"key":"50453_CR47","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1111\/ajt.12803","volume":"14","author":"D Toki","year":"2014","unstructured":"Toki, D. et al. The role of macrophages in the development of human renal allograft fibrosis in the first year after transplantation. Am. J. Transplant. 14, 2126\u20132136 (2014).","journal-title":"Am. J. Transplant."},{"key":"50453_CR48","doi-asserted-by":"publisher","first-page":"e0156900","DOI":"10.1371\/journal.pone.0156900","volume":"11","author":"T Bergler","year":"2016","unstructured":"Bergler, T. et al. Infiltration of macrophages correlates with severity of allograft rejection and outcome in human kidney transplantation. PloS one. 11, e0156900 (2016).","journal-title":"PloS one"},{"key":"50453_CR49","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1034\/j.1600-6143.2003.00068.x","volume":"3","author":"MD Jose","year":"2003","unstructured":"Jose, M. D., Le Meur, Y., Atkins, R. C., Chadban, S. J. & Rajotte, R. V. Blockade of macrophage colony-stimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection. Am. J. Transplant. 3, 294\u2013300 (2003).","journal-title":"Am. J. Transplant."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50453-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50453-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50453-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:15:49Z","timestamp":1783462549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50453-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50453"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50453-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21022"}}